Baudax Bio To Participate In The JMP Securities Life Sciences Conference

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc.
Author:
Publish date:

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (BXRX) , a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced Gerri Henwood, the Company's President and Chief Executive Officer, will participate in a fireside chat virtually at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 4:00 p.m. ET.

A live webcast of the fireside chat will be available on the "Presentations" page within the investors section of the Baudax Bio website at  https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings. The launch of Baudax Bio's first commercial product ANJESO ® began in mid-2020. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies. For more information, please visit  www.baudaxbio.com.

CONTACT:  

Investor Relations Contact:Argot PartnersSam Martin / Claudia Styslinger(212) 600-1902 baudaxbio@argotpartners.com

Media Contact:Argot PartnersDavid Rosen(212) 600-1902 david.rosen@argotpartners.com